Ratings by Jefferies (Matthew Stanton)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/23/2026 | BioLife Solutions | BLFS | Downgrade | Hold (Buy) |
31.15 (30.77) |
-1.22% | Details | |
| 5/6/2026 | Azenta, Inc. | AZTA | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2026 | Repligen | RGEN | Maintain | Hold (N/A) |
|
Details | ||
| 2/4/2026 | Azenta, Inc. | AZTA | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Standard BioTools Inc | LAB | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | Azenta, Inc. | AZTA | Upgrade | Buy (Hold) |
31.36 (28.30) |
-9.76% | Details | |
| 10/28/2025 | Repligen | RGEN | Maintain | Hold (N/A) |
|
Details | ||
| 9/11/2025 | Repligen | RGEN | Maintain | Hold (N/A) |
|
Details | ||
| 8/6/2025 | CryoPort | CYRX | Maintain | Hold (N/A) |
|
Details | ||
| 4/29/2025 | Repligen | RGEN | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2025 | CryoPort | CYRX | Maintain | Hold (N/A) |
|
Details | ||
| 2/20/2025 | Repligen | RGEN | Maintain | Hold (N/A) |
|
Details | ||
| 2/5/2025 | Azenta, Inc. | AZTA | Maintain | Hold (N/A) |
|
Details | ||
| 8/7/2024 | CryoPort | CYRX | Downgrade | Hold (Buy) |
7.79 (16.03) |
105.78% | Details | |
| 5/1/2024 | Repligen | RGEN | Maintain | Hold (N/A) |
|
Details | ||
| 4/4/2024 | CryoPort | CYRX | New Coverage | Buy (N/A) |
17.91 (7.79) |
-56.5% | Details | |
| 4/4/2024 | Azenta, Inc. | AZTA | New Coverage | Hold (N/A) |
58.82 (31.36) |
-46.68% | Details | |
| 4/4/2024 | Standard BioTools Inc | LAB | New Coverage | Buy (N/A) |
2.64 (0.88) |
-66.67% | Details | |
| 4/4/2024 | BioLife Solutions | BLFS | New Coverage | Buy (N/A) |
17.60 (30.77) |
74.83% | Details |
